论文部分内容阅读
[目的]探讨肝癌患者经恩度联合肝动脉化疗栓塞术(TACE)治疗后血清血管内皮生长因子(VEGF)、结缔组织生长因子(CTGF)、骨桥蛋白(OPN)以及基质金属蛋白酶(MMP-9)的水平变化。[方法]选择2014年1月~2016年1月在我院治疗的肝癌患者112例,随机分为观察组和对照组,每组56例。对照组采用TACE治疗,观察组在对照组基础上联合恩度治疗,观察治疗前后2组患者的血清指标变化、短期疗效及不良反应。[结果]治疗前2组患者的血清VEGF、CTGF、OPN、MMP-9指标差异无统计学意义(P>0.05),术后30d,对照组患者的各项血清指标较治疗前均明显上升(P<0.05);而观察组患者的各项血清指标水平较治疗前有所降低,但无明显变化(P>0.05),且各项指标均明显低于对照组治疗后水平(P<0.05);观察组患者有效率73.21%明显高于对照组的39.29%(P<0.05);观察组的不良反应发生率为14.29%与对照组的8.93%差异无统计学意义(P>0.05)。[结论]恩度联合TACE能够有效抑制肝癌患者血清VEGF、CTGF、OPN、MMP-9表达,短期效果显著,且无严重不良反应。
[Objective] To investigate the changes of serum vascular endothelial growth factor (VEGF), connective tissue growth factor (CTGF), osteopontin (OPN) and matrix metalloproteinases (MMP-9) in patients with hepatocellular carcinoma after enamel combined with transcatheter arterial chemoembolization (TACE) 9) the level of change. [Methods] One hundred and twenty-one patients with hepatocellular carcinoma who were treated in our hospital from January 2014 to January 2016 were randomly divided into observation group and control group with 56 cases in each group. The control group was treated with TACE. The observation group was enrolled in the control group on the basis of Ende treatment, and the changes of serum indexes, short-term curative effects and adverse reactions in the two groups before and after treatment were observed. [Results] There was no significant difference in the serum VEGF, CTGF, OPN and MMP-9 levels between the two groups before treatment (P> 0.05). At 30 days after operation, the serum indexes of the control group were significantly higher than those before treatment P <0.05). However, the serum levels of the observation group were lower than those before treatment, but there was no significant change (P> 0.05), and all indexes were significantly lower than those of the control group after treatment (P <0.05) . The effective rate in observation group was 73.21%, which was significantly higher than that in control group (39.29%, P <0.05). The incidence of adverse reactions in observation group was 14.29%, which was not significantly different from that in control group (8.93%, P> 0.05). [Conclusion] Endo combined with TACE can effectively inhibit the expression of VEGF, CTGF, OPN and MMP-9 in patients with hepatocellular carcinoma, with short-term effect and no serious adverse reactions.